

United States Patent and Trademark Office

M

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/031,569	01/22/2002	Haruji Sawada	217865USOJPCT	6387	
22850	7590 05/20/2004		EXAMINER		
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET ALEXANDRIA, VA 22314			LILLING, HERBERT J		
			ART UNIT	PAPER NUMBER	
	,		1651		
			DATE MAILED: 05/20/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Applica	ation No.	Applicant(s)				
		,569	SAWADA ET AL.				
Office Action Summary	Examir	ner	Art Unit				
	HERBE	RT J LILLING	1651				
The MAILING DATE of this commun	nication appears on	the cover sheet with th	e correspondence address				
A SHORTENED STATUTORY PERIOD F THE MAILING DATE OF THIS COMMUN - Extensions of time may be available under the provisions after SIX (6) MONTHS from the mailing date of this com - If the period for reply specified above is less than thirty (3 - If NO period for reply is specified above, the maximum si - Failure to reply within the set or extended period for reply Any reply received by the Office later than three months earned patent term adjustment. See 37 CFR 1.704(b).	ICATION. s of 37 CFR 1.136(a). In no munication. 30) days, a reply within the statutory period will apply and will, by statute, cause the a	event, however, may a reply be statutory minimum of thirty (30) d will expire SIX (6) MONTHS for application to become ABANDO	e timely filed days will be considered timely. rom the mailing date of this communication. DNED (35 U.S.C. § 133).				
Status							
1) Responsive to communication(s) file	ed on 12 March 200	04.					
	2b) This action is						
	· · · · · · · · · · · · · · · · · · ·						
Disposition of Claims	p		*				
4) ⊠ Claim(s) <u>1-32</u> is/are pending in the a 4a) Of the above claim(s) <u>4-14 and -</u> 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1-32</u> are subject to restricting	.17-19 is/are withdra		٦.				
Application Papers							
9)☐ The specification is objected to by th	e Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any obje	ction to the drawing(s) be held in abeyance.	See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including	the correction is requ	uired if the drawing(s) is	objected to. See 37 CFR 1.121(d).				
11)☐ The oath or declaration is objected to	by the Examiner. I	Note the attached Offi	ce Action or form PTO-152.				
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim a) All b) Some * c) None of: 1. Certified copies of the priority 2. Certified copies of the priority 3. Copies of the certified copies application from the Internation * See the attached detailed Office action	documents have be documents have be of the priority docur anal Bureau (PCT R	een received. een received in Applic ments have been rece ule 17.2(a)).	ation No ived in this National Stage				
Attachment(s)							
1) Notice of References Cited (PTO-892)	TO 040)	4) Interview Summa					
 Notice of Draftsperson's Patent Drawing Review (P3) Information Disclosure Statement(s) (PTO-1449 or Paper No(s)/Mail Date 	-	Paper No(s)/Mail 5) Notice of Informa 6) Other:	Date I Patent Application (PTO-152)				

Art Unit: 1651

- 1. Receipt is acknowledged of the amendment and arguments filed March 12, 2004.
- 2. Claims 1-32 are now pending in this application.
- 3. In view of the arguments and amendments to the claims, this Examiner has required an additional restriction based on the argument "...are not so linked to form a single inventive concept." has been found to be in error. Applicant will have the opportunity to rebut this issue by the following additional restriction requirement in accordance with requirement that all of the inventions are "so linked to form a single inventive concept..." in view of prior art that renders Invention A unpatentable.

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group A, claim(s) 1 and 2, drawn to a cholesterol-lowering agent containing, as an active ingredient, at least one yeast belonging to Kluyveromyces marxianus or Klyveromyces lactis.

Group B, claim(s) 3, 21-27, drawn to a food or drink for reducing cholesterol containing as a yeast belonging to Kluyveromyces marxianus or Kluyveromyces lactis.

Claim 20 will be examined with this group which claim does not require that the food or drink reduce cholesterol.

Application/Control Number: 10/031,569 Page 3

Art Unit: 1651

Group C, claims 15-16 and 28-32, drawn to a treatment for reducing cholesterol containing, as an active ingredient, at least one yeast belonging to Kluyveromyces marxianus or Klyveromyces lactis.

The following prior art, <u>5811293</u>, <u>5679557</u> or <u>5679557</u>, teach that the yeast are well known as well as being within the scope of the broad claimed language. If Applicant elects, Group A and Group A claim(s) is(are) found allowable, the restriction requirement submitted above will be withdrawn.

The restriction requirement is proper according to the rules under PCT practice that the claims are not so linked to form a single general inventive concept under PCT Rule 13.1.

4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

5. Rejoinder of claims will be in accordance with the following: F.P.: Ochiai/Brouwer Rejoinder form paragraph

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in

Art Unit: 1651

accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Examiner Lilling whose telephone number is 571-272-0918** and **Fax Number** is (703) 872-9306 or SPE Michael Wityshyn whose telephone number is 571-272-0926. Examiner can be reached Monday-Thursday from about 5:30 A.M. to about 3:00 P.M. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

H.J.Lilling: HJL (703) 308-2034 Art Unit <u>1651</u> May 17, 2004

> Dr. Herbert J. Lilling Primary Examiner

Group 1600 Art Unit 1651